Vera Therapeutics (VERA) is in focus after the US Food and Drug Administration granted accelerated approval for TRUTAKNA, the company’s first commercial product for adults with primary IgA nephropathy at risk for disease progression.

The FDA approval of TRUTAKNA comes after a strong run for Vera Therapeutics, with the 1 year total shareholder return of 74.25% contrasting with a year to date share price return that is down 12.73% and shorter term momentum picking up on a 1 month share price return of 33.39%.

If this kind of catalyst driven move has your attention, it is a good time to see what other healthcare stocks using AI are doing via our 40 healthcare AI stocks

After a sharp 1 month rebound following TRUTAKNA’s accelerated approval, Vera Therapeutics now sits at a very different starting line. Do the current valuation and risk profile still tilt in favour of new buyers?

Price to Book of 6.1x: Is it justified?

Vera Therapeutics last closed at $42.43, and on a P/B of 6.1x it screens as expensive versus the broader US Biotechs sector, even though some models flag it as trading well below certain fair value estimates.

P/B compares the market value of a company to its net assets, which can be a useful yardstick for early stage biotechs where earnings and revenue are still limited, as is the case for Vera Therapeutics with reported revenue of $0 and ongoing net losses of $368.953m.

Here, the picture is mixed. On one hand, Vera Therapeutics is described as trading 92.5% below an internal fair value estimate and also below an SWS DCF model future cash flow value of $562.37. Together, these suggest the share price is well under those valuation reference points. On the other hand, the P/B of 6.1x is higher than the US Biotechs industry average of 2.8x, although it sits below a peer group average P/B of 8.1x, so the market is pricing Vera somewhere between the broader sector and closer peer companies.

Result: Price-to-book of 6.1x (ABOUT RIGHT)

However, Vera Therapeutics still carries clear risks, including its current net loss of $368.953m and reliance on successful commercialization of TRUTAKNA to support its valuation.

Another View on Vera Therapeutics’ Valuation

The P/B of 6.1x makes Vera Therapeutics look expensive against the wider US Biotechs industry, but the SWS DCF model points the other way, with a future cash flow value of $562.37 versus a share price of $42.43. If that gap closes, which signal will prove more useful for you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vera Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Feeling torn between the upside and the risks around Vera Therapeutics after TRUTAKNA’s approval and recent share price swings? Take a closer look at the full picture, including both the concerns and potential rewards flagged in our analysis, by checking the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Vera Therapeutics?

If Vera Therapeutics has sharpened your focus on where capital goes next, broaden your watchlist with a few targeted stock ideas that could reshape your opportunity set.

• Zero in on potential mispricings by scanning a curated set of 44 high quality undervalued stocks that combine strong fundamentals with attractive valuations.
• Strengthen your income stream by reviewing a hand picked group of 9 dividend fortresses that offer higher yields with a focus on resilience.
• Stay a step ahead of the crowd by checking a screener containing 19 high quality undiscovered gems before they attract wider market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.